Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by James Galloway and Andrew Cope.
James Galloway
Connection Strength
0.347
Andrew Cope
  1. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Sep; 3(9):e627-e637.
    View in: PubMed
    Score: 0.060
  2. Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulm Pharmacol Ther. 2021 08; 69:102035.
    View in: PubMed
    Score: 0.059
  3. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021 04 06; 60(4):1585-1587.
    View in: PubMed
    Score: 0.059
  4. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. 2021 07; 185(1):80-90.
    View in: PubMed
    Score: 0.058
  5. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jul 31; 21(1):690.
    View in: PubMed
    Score: 0.056
  6. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 08; 21(1):626.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.